¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"flow related enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • continuous-flow resectoscope
    Áö¼Ó°ü·ùÀýÁ¦°æ
  • counter flow
    ¸ÂÈ帧
  • extrahepatic blood flow
    °£¿ÜÇ÷·ù·®
  • effective renal blood flow
    À¯È¿ÄáÆÏÇ÷·ù·®, À¯È¿½ÅÀåÇ÷·ù·®
  • effective renal plasma flow
    À¯È¿ÄáÆÏÇ÷ÀåÀ¯·®, À¯È¿½ÅÀåÇ÷ÀåÀ¯·®
  • estimated hepatic blood flow
    ÃßÁ¤°£Ç÷·ù·®
  • flow
    1. È帧, ·ù, À¯µ¿ 2. À¯·®
  • flow artifact
    È帧Àΰø¹°, È帧Çã»ó, À¯µ¿Àΰø¹°
  • flow chart
    È帧µµ, ¼ø¼­µµ
  • flow compensation
    È帧º¸»ó
  • flow compensation gradient technique
    È帧º¸»ó±â¿ï±â±â¹ý
  • flow cytometer
    È帧¼¼Æ÷ÃøÁ¤±â
  • flow cytometry
    È帧¼¼Æ÷ÃøÁ¤(¹ý)
  • flow diagram
    È帧µµÇ¥
  • flow rate
    1. À¯¼Ó 2. À¯·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • flow artifact
    È帧Àΰø¹°, È帧Çã»ó, À¯µ¿Àΰø¹°
  • back flow
    ¿ª·ù, °Å²ÜÈ帧, µÚÈ帧
  • blood flow
    Ç÷·ù, ÇÇÈ帧
  • blood flow meter
    Ç÷·ù°è
  • blood flow rate
    Ç÷·ù·®, Ç÷·ù¼Óµµ
  • blood flow velocity
    ÇÇÈ帧¼Óµµ, Ç÷·ù¼Óµµ
  • bulk flow
    µ¢ÀÌÈ帧, ¿ëÀûÈ帧
  • cerebrospinal fluid flow void sign
    ³úô¼ö¾×È帧¼Ò½Ç¡ÈÄ
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • color flow mapping
    »öÇ÷·ùÁöµµÈ­
  • continuous-flow resectoscope
    Áö¼Ó°ü·ùÀýÁ¦°æ
  • counter flow
    ¸ÂÈ帧
  • flow chart
    È帧µµ, ¼ø¼­µµ
  • flow compensation
    È帧º¸»ó
  • flow cytometer
    È帧¼¼Æ÷ÃøÁ¤±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • aqueous flow
    ¹æ¼öÈ帧, ¹æ¼ö·ù
  • gas flow
    °¡½ºÀ¯·®.
  • gas flow meter
    ±âüÀ¯¼Ó°è(¡­êüáÜͪ).
  • hepatic blood flow
    °£Ç÷·ù(·®)(ÊÜúì×µ).
  • hepatic blood flow
    °£Ç÷·ù(·®).
  • high flow method
    °íÀ¯·®¹ý(ÍÔêüåÖÛö).
  • in-flow effect
    À¯ÀÔ È¿°ú
  • in-plane flow misregistration
    Æò¸é³» À¯µ¿ ¿Àµî·Ï
  • inspiratory triggering flow
    Èí±âÀ¯¹ß±â·ù.
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pulmonary blood flow
    ÆóÇ÷·ù·®(øËúìêüåÖ).
  • pulmonary flow resistance
    Æó±â·ùÀúÇ×(øËѨêüî½ù÷).
  • pyelointerstitial back flow
    ½Å¿ì°£Áú¼º¿ª·ù
  • pyelotubular back flow
    ½Å¿ì¼¼¿ä°ü¼º¿ª·ù
  • quantitative flow measurement
    Á¤·®Àû À¯·® ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    Áõ°­
  • enhancement media
    Áõ°­¹èÁö
  • enhancement, immune
    ¸é¿ªÁõ°­Çö»ó
  • enhancement, immunological
    ¸é¿ªÁõ°­Çö»ó
  • immune enhancement
    ¸é¿ªÇÐÀûÃËÁø (Á¾¾çÁõ½ÄÀÇ)
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • inflow enhancement
    À¯ÀÔ Áõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µÁõ°­, °æµµÀÇ Á¶¿µÁõ°­
  • oxygen enhancement ratio (OER)
    »ê¼ÒÁõ°­ºñ
  • oxygen enhancement ratio =OER
    »ê¼ÒÈ¿°úÁõ°­·ü(¡­üùÍýñòË­ëÒ).
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µÁõ°­
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • flow
    ±â·ù, À¯·®, È帧
  • flow artifact
    À¯µ¿Àΰø¹°
  • flow chart
    È帧µµ, ¼ø¼­µµ
  • flow compensated pulse sequence
    À¯µ¿º¸»óÆÞ½º¿¬¼â
  • flow compensation
    À¯µ¿º¸»ó
  • flow compensation gradient technique
    À¯µ¿º¸»ó°æ»ç±â¹ý
  • flow cytometry
    À¯¼Ó¼¼Æ÷ºÐ¼®¹ý
  • flow encoding axis
    À¯µ¿ºÎȣȭÃà
  • flow misregistration
    À¯µ¿¿Àµî·Ï
  • flow phenomena
    À¯µ¿Çö»ó
  • flow sensitive gradient echo sequence
    À¯µ¿¹Î°¨°æ»ç¿¡ÄÚ¿¬¼â
  • flow signal
    À¯µ¿½ÅÈ£
  • flow velocity profile
    À¯¼ÓºÐÆ÷»ó
  • flow void
    À¯µ¿°ø¹é
  • flow void sign
    À¯µ¿°ø¹é¡ÈÄ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PTHRP, PTHrP parathyroid-hormone-related peptide; parathyroid-hormone-related protein
OER Oxygen Enhancement Ratio
ADE acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest...
DEPT distortionless enhancement by polarization transfer
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SER Sensitizer enhancement ratios
TER Thermal Enhancement Ratio
ARMD AGE-RELATED MACULAR DEGENERATION
A.R.C. AIDS Related Complex
ARL AIDS)-related lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • coronary blood flow
    °üÇ÷·ù, °ü»ó Ç÷·ù
  • counter current flow
    ¿ªÈ帧, °Å²Ù·Î È帧, ¿ª·ù
  • counter flow
    ´ëÇâ·ù, ¿ª·ù, ¹Ý·ù
  • flow amount
    À¯·®
  • flow compensated pulse sequence
    À¯µ¿ º¸»ó ÆÞ½º ¿¬¼â
  • flow compensation gradient technique
    À¯µ¿ º¸»ó °æ»ç ±â¹ý
  • flow cytometry
    À¯¼Ó ¼¼Æ÷ ºÐ¼®¹ý
  • flow meter
    À¯·®°è, À¯¼Ó°è
    ¾×ü ¶Ç´Â ±âüÀÇ À¯¼ÓÀ» ÃøÁ¤ÇÏ´Â ±â±¸.
  • flow phenomena
    À¯µ¿ Çö»ó
  • flow resistance
    È帧 ÀúÇ×, À¯·® ÀúÇ×
  • flow signal
    À¯µ¿ ½ÅÈ£
  • flow void
    À¯µ¿ °ø¹é
  • flow volume curve
    À¯·®±â·® °î¼±
  • high intensity proton flow
    °í°­µµ ¾çÀÚÀ¯µ¿
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
prosthesis-related infections Infections resulting from the implantation of prosthetic devices. The infections may be acquired from intraoperative contamination (early) or haematogenously acquired from other sites (late).
(12 Dec 1998)
src-related intestinal kinase <enzyme> An intracellular epithelial cell tyrosine kinase; shares 80% homology with human tyrosine kinase brk; has 451 amino acid residues; amino acid sequence given in first source
Registry number: EC 2.7.1.-
Synonym: sik protein, sik gene product
(26 Jun 1999)
substance-related disorders These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure.
(12 Dec 1998)
diabetes related peptide <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide.
(15 Oct 1997)
diagnosis-related group A classification of patients by diagnosis or surgical procedure (sometimes including age) into major diagnostic categories (each containing specific diseases, disorders, or procedures) for the purpose of determining payment of hospitalization charges, based on the premise that treatment of similar medical diagnoses generate similar costs.
A scheme for billing for medical and especially hospital services by combining diseases into groups according to the resources needed for care, arranged by diagnostic category. A dollar value is assigned to each group as the basis of payment for all cases in that group, without regard to the actual cost of care or duration of hospitalization of any individual case, as a mechanism to motivate health-care providers to economise.
(05 Mar 2000)
diagnosis-related groups A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.
(12 Dec 1998)
diseases, obesity-related Obesity increases the risk of developing a number of diseases including: Type 2 (adult-onset) diabetes High blood pressure (hypertension) Stroke (cerebrovascular accident or CVA) Heart attack (myocardial infarction or MI) Heart failure (congestive heart failure) Cancer (only certain forms such as prostate and colon cancer) Gallstones and gall bladder disease (cholecystitis) Gout and gouty arthritis Osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back Sleep apnea (failure to breath normally during sleep, lowering blood oxygen) Pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
islet cell antigen-related protein-tyrosine phosphatase <enzyme> Receptor-like autoantigen found in insulin-dependent diabetes; genbank l76258
Registry number: EC 3.1.3.-
Synonym: iar ptp
(26 Jun 1999)
obesity-related diseases Obesity increases the risk of developing a number of diseases including: type 2 (adult-onset) diabetes high blood pressure (hypertension) stroke (cerebrovascular accident or cva) heart attack (myocardial infarction or mi) heart failure (congestive heart failure) cancer (only certain forms such as prostate and colon cancer) gallstones and gall bladder disease (cholecystitis) gout and gouty arthritis osteoarthritis (degenerative arthritis) of the knees, hips, and the lower back sleep apnea (failure to breath normally during sleep, lowering blood oxygen) pickwickian syndrome (obesity, red face, underventilation, and drowsiness).
(12 Dec 1998)
opioid-related disorders Disorders related or resulting from abuse or mis-use of opioids.
(12 Dec 1998)
event-related potentials, p300 A late-appearing component of the event-related potential. P stands for positive voltage potential and 300 represents 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity.
(12 Dec 1998)
fos-related antigen <molecular biology> A group of phosphoproteins found in the cell nucleus which are structurally similar to the fos oncogene's gene product.
(06 Mar 1998)
FYN-related kinase <enzyme> 49% identical to human fyn and 47% to human src; genbank u00803
Registry number: EC 2.7.1.-
Synonym: frk protein, frk gene product
(26 Jun 1999)
light chain-related amyloidosis A form of primary amyloidosis in which the fibrillar amyloid deposits are derived from the amino terminal variable region of the light chains of immunoglobulin; seen in B-lymphocyte and plasma-cells dyscrasias.
(05 Mar 2000)
localization related epilepsy A clinically diverse group of epilepsy syndromes, some benign, some progressive. Many are hereditary with mendelian and nonmendelian mitochondrial inheritance. All are characterised by the occurrence of myoclonus, which may be limited or predominate in the condition. Specific syndromes include cherry red spot myoclonus syndrome, ceroid lipofuscinosis, myoclonic epilepsy with ragged red fibres, and Baltic myoclonus.
Synonym: localization related epilepsy.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á